Endpoints in Heart Failure Drug Development
Volume: 8, Issue: 6, Pages: 429 - 440
Published: Jun 1, 2020
Abstract
Heart failure (HF) patients experience a high burden of symptoms and functional limitations, and morbidity and mortality remain high despite successful therapies. The majority of HF drugs in the United States are approved for reducing hospitalization and mortality, while only a few have indications for improving quality of life, physical function, or symptoms. Patient-reported outcomes that directly measure patient’s perception of health status...
Paper Details
Title
Endpoints in Heart Failure Drug Development
Published Date
Jun 1, 2020
Volume
8
Issue
6
Pages
429 - 440
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History